FDA Grants InBios First Marketing Rights for Anthrax POC Test
InBios has been granted the U.S. Food and Drug Administration’s (FDA) first marketing rights for an anthrax point-of-care (POC) test.
Read MorePosted by Andy Lundin | Mar 3, 2023 | POC Rapid Assays |
InBios has been granted the U.S. Food and Drug Administration’s (FDA) first marketing rights for an anthrax point-of-care (POC) test.
Read MorePosted by Andy Lundin | Mar 2, 2023 | Covid 19 |
Cue Health and Pfizer are collaborating to raise awareness for those with underlying conditions of the risks of progressing to severe COVID.
Read MorePosted by Andy Lundin | Feb 24, 2023 | Covid 19 |
The U.S. FDA issued an emergency use authorization for the first over-the-counter at-home test that can differentiate influenza and COVID.
Read MorePosted by Chris Wolski | Feb 16, 2023 | Computing Systems, Middleware & Software |
There’s no hard and fast rules, but following these seven best practices, you can make your LIMS/LIS implementation a success.
Read MorePosted by Andy Lundin | Feb 15, 2023 | Diagnostic Technologies |
Hurdle and CloudLIMS entered into a strategic partnership that marks the integration between a DaaS platform and a SaaS LIMS provider.
Read More